Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
Opdualag chalks up another failure, this time in the extension of an approved use.
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
AbbVie follows Gilead in throwing Xilio a lifeline.
